618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target
R. Houston Thompson(Dalhousie University), Eugene D. Kwon(BC Children's Hospital), Kent G. Krejci(Mayo Clinic), Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Lieping Chen(Yale Cancer Center), Haidong Dong(Mayo Clinic in Arizona), Christine M. Lohse(Quantitative BioSciences), Bradley C. Leibovich(Mayo Clinic in Arizona), John C. Cheville(Mayo Clinic), W. Scott Webster(Mayo Clinic), John R. Lobo(Mayo Clinic), Shomik Sengupta(Mayo Clinic), Michael L. Blute(Harvard University), Horst Zincke(Mayo Clinic), Michael D. Gillett(Mayo Clinic)
Cited by 387
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
|Journal of Clinical Investigation|2015|1.4k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
|Proceedings of the National Academy of Sciences|2004|767